{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:45:19Z","timestamp":1790163919408,"version":"4.1.0"},"reference-count":47,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare condition in which maternal alloantibodies to fetal platelets cause fetal thrombocytopenia that may lead to intracranial hemorrhage (ICH). Off-label intravenous immunoglobulin (IVIg) has for 30 years been the standard of care for pregnant women who previously have had a child with FNAIT. The efficacy of this treatment has never been tested in a placebo-controlled clinical trial. Although IVIg treatment may improve the neonatal outcome in women who previously have had a child with FNAIT-associated ICH, the question is whether IVIg is necessary for all immunized pregnant women at risk of having a child with FNAIT. The results from some recent publications suggest that antenatal IVIg treatment is not necessary for women who are (1) HPA-1a-immunized and HLA-DRB3*01:01-negative, (2) HPA-1a-immunized with a previous child with FNAIT but without ICH or (3) HPA-5b-immunized. If IVIg is not used for these categories of pregnant women, the amount of IVIg used in pregnant women with platelet antibodies would be reduced to less than \u00bc of today\u2019s use. This is important because IVIg is a scarce resource, and the collection of plasma for the treatment of one pregnant woman is not only extremely expensive but also requires tremendous donor efforts.<\/jats:p>","DOI":"10.3390\/jcm12175492","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T10:23:40Z","timestamp":1692872620000},"page":"5492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pregnant Women at Low Risk of Having a Child with Fetal and Neonatal Alloimmune Thrombocytopenia Do Not Require Treatment with Intravenous Immunoglobulin"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-242X","authenticated-orcid":false,"given":"Jens","family":"Kjeldsen-Kragh","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Transfusion Medicine, University and Regional Laboratories, Akutgatan 8, 221 85 Lund, Sweden"},{"name":"Department of Laboratory Medicine, University Hospital of North Norway, 9019 Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7571-8362","authenticated-orcid":false,"given":"Gregor","family":"Bein","sequence":"additional","affiliation":[{"name":"Institute for Clinical Immunology, Transfusion Medicine and Hemostasis, Justus-Liebig-University, 35392 Giessen, Germany"},{"name":"German Center for Feto-Maternal Incompatibility, University Hospital Giessen and Marburg, Campus Giessen, 35392 Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Tiller","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University Hospital of North Norway, 9019 Troms\u00f8, Norway"},{"name":"Women\u2019s Health and Perinatology Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, 9019 Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102704","DOI":"10.1016\/j.transci.2019.102704","article-title":"Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia","volume":"59","author":"Winkelhorst","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1542\/peds.2013-3320","article-title":"Incidence and consequences of neonatal alloimmune thrombocytopenia: A systematic review","volume":"133","author":"Kamphuis","year":"2014","journal-title":"Pediatrics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bjh.18173","article-title":"Anti-human platelet antigen-5b antibodies and fetal and neonatal alloimmune thrombocytopenia; incidental association or cause and effect?","volume":"198","author":"Alm","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-3148.2004.00535.x","article-title":"The natural history of maternal immunization against foetal platelet alloantigens","volume":"14","author":"Ohto","year":"2004","journal-title":"Transfus. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0198-8859(90)90104-W","article-title":"HLA-DRw52a is involved in alloimmunization against PL-A1 antigen","volume":"27","author":"Valentin","year":"1990","journal-title":"Hum. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1182\/bloodadvances.2020002137","article-title":"Fetal\/neonatal alloimmune thrombocytopenia: A systematic review of impact of HLA-DRB3*01:01 on fetal\/neonatal outcome","volume":"4","author":"Fergusson","year":"2020","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/ATVBAHA.116.307281","article-title":"Antiendothelial alphavbeta3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal\/Neonatal Alloimmune Thrombocytopenia","volume":"36","author":"Santoso","year":"2016","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_8","first-page":"337a","article-title":"Neonatal alloimmune thrombocytopenia (NAlT): A prospective case accumulation study","volume":"23","author":"Bussel","year":"1988","journal-title":"Pediatr. Res."},{"key":"ref_9","first-page":"154","article-title":"Isoimmune Neonatal Thrombocytopenic Purpura","volume":"23","author":"Pearson","year":"1964","journal-title":"Clin. Ther. Consid. Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000415160","article-title":"Neonatal alloimmune thrombocytopenia: A clinical perspective","volume":"54","author":"Blanchette","year":"1988","journal-title":"Curr. Stud. Hematol. Blood Transfus."},{"key":"ref_11","first-page":"363","article-title":"348 cases of suspected neonatal alloimmune thrombocytopenia","volume":"1","author":"Kiefel","year":"1989","journal-title":"Lancet"},{"key":"ref_12","unstructured":"Colman, R.W., Hirsh, J., Manier, V.J., and Salzman, E.W. (1982). Hemostasis and Thrombosis: Basic Principles and Clinical Practice, J.B. Lippincott."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJM198811243192103","article-title":"Antenatal treatment of neonatal alloimmune thrombocytopenia","volume":"319","author":"Bussel","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_14","first-page":"CD004226","article-title":"Antenatal interventions for fetomaternal alloimmune thrombocytopenia","volume":"5","author":"Rayment","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2016-10-739656","article-title":"Antenatal management in fetal and neonatal alloimmune thrombocytopenia: A systematic review","volume":"129","author":"Winkelhorst","year":"2017","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102710","DOI":"10.1016\/j.transci.2019.102710","article-title":"The use of IVIg in fetal and neonatal alloimmune thrombocytopenia\u2014Principles and mechanisms","volume":"59","author":"Wabnitz","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_17","unstructured":"National Blood Authority (2023, August 15). Australia, Available online: https:\/\/www.blood.gov.au\/system\/files\/documents\/Fetal-and-neonatal-alloimmune-thrombocytopenia-FNAIT-CV3.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/1471-0528.15642","article-title":"Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT): Scientific Impact Paper No. 61","volume":"126","author":"Regan","year":"2019","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/17474086.2017.1346471","article-title":"Fetal and neonatal alloimmune thrombocytopenia: Evidence based antenatal and postnatal management strategies","volume":"10","author":"Winkelhorst","year":"2017","journal-title":"Expert. Rev. Hematol."},{"key":"ref_20","first-page":"1783","article-title":"Effects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyle","volume":"29","author":"Rossi","year":"2015","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/11537660-000000000-00000","article-title":"Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use","volume":"24","author":"Cherin","year":"2010","journal-title":"BioDrugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1423-0410.2003.00302.x","article-title":"Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?","volume":"84","author":"Radder","year":"2003","journal-title":"Vox Sang"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3324\/haematol.12515","article-title":"A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn","volume":"93","author":"Killie","year":"2008","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/1471-0528.13343","article-title":"True risk of fetal\/neonatal alloimmune thrombocytopenia in subsequent pregnancies: A prospective observational follow-up study","volume":"123","author":"Tiller","year":"2016","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"506.e1","DOI":"10.1016\/j.ajog.2022.04.044","article-title":"Antenatal intravenous immunoglobulins in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia: Comparison of neonatal outcome in treated and nontreated pregnancies","volume":"227","author":"Ernstsen","year":"2022","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102711","DOI":"10.1016\/j.transci.2019.102711","article-title":"Fetal and neonatal alloimmune thrombocytopenia\u2014The Norwegian management model","volume":"59","author":"Tiller","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/bjh.17731","article-title":"Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia","volume":"195","author":"Porcelijn","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/trf.14394","article-title":"Intracranial hemorrhages in neonates born from 32 weeks of gestation-low frequency of associated fetal and neonatal alloimmune thrombocytopenia: A register-based study","volume":"58","author":"Refsum","year":"2018","journal-title":"Transfusion"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V79.9.2480.2480","article-title":"Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia\/IIa alloantibody (anti-HPA-5b)","volume":"79","author":"Warkentin","year":"1992","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/trf.13274","article-title":"Fetal and neonatal alloimmune thrombocytopenia: Predictive factors of intracranial hemorrhage","volume":"56","author":"Delbos","year":"2016","journal-title":"Transfusion"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1148\/radiol.2422060133","article-title":"Intracranial hemorrhage in asymptomatic neonates: Prevalence on MR images and relationship to obstetric and neonatal risk factors","volume":"242","author":"Looney","year":"2007","journal-title":"Radiology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0140-6736(90)91842-X","article-title":"Very early intracranial haemorrhage in alloimmune fetal thrombocytopenia","volume":"336","author":"Giovangrandi","year":"1990","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0895-6111(92)90128-V","article-title":"Prenatal recognition of central nervous system complications of alloimmune thrombocytopenia","volume":"16","author":"Kuhn","year":"1992","journal-title":"Comput. Med. Imaging Graph."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/pd.1970121116","article-title":"Neonatal alloimmune thrombocytopenia due to anti-P1A1 (anti-HPA-1a): Importance of paternal and fetal platelet typing for assessment of fetal risk","volume":"12","author":"Lipitz","year":"1992","journal-title":"Prenat. Diagn."},{"key":"ref_35","first-page":"137","article-title":"Devastating sequelae of alloimmune thrombocytopenia: An entity that deserves more attention","volume":"5","author":"Khouzami","year":"1996","journal-title":"J. Matern. Fetal Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"135.e1","DOI":"10.1016\/j.ajog.2010.03.011","article-title":"Intracranial hemorrhage in alloimmune thrombocytopenia: Stratified management to prevent recurrence in the subsequent affected fetus","volume":"203","author":"Bussel","year":"2010","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1111\/trf.17144","article-title":"Clinical and laboratory predictors of fetal and neonatal alloimmune thrombocytopenia","volume":"62","author":"Matusiak","year":"2022","journal-title":"Transfusion"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/pd.6113","article-title":"COL4A1\/COL4A2 and inherited platelet disorder gene variants in fetuses showing intracranial hemorrhage","volume":"42","author":"Coste","year":"2022","journal-title":"Prenat. Diagn."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ajog.2023.01.024","article-title":"Fetal and Neonatal Alloimmune Thrombocytopenia in 2022","volume":"228","author":"Bussel","year":"2023","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_40","unstructured":"(2023, August 15). Pharmaceutical Technology. Available online: https:\/\/www.pharmaceutical-technology.com\/features\/immune-globulin-shortages\/."},{"key":"ref_41","unstructured":"(2023, August 15). Verywellfit. Available online: https:\/\/www.verywellfit.com\/average-weight-for-a-woman-statistics-2632138."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/AOG.0b013e31823403f4","article-title":"Fetal and neonatal alloimmune thrombocytopenia: A management algorithm based on risk stratification","volume":"118","author":"Pacheco","year":"2011","journal-title":"Obs. Gynecol."},{"key":"ref_43","unstructured":"(2023, August 15). Available online: https:\/\/www.howmuchisit.org\/how-much-does-ivig-cost\/."},{"key":"ref_44","unstructured":"Jagschies, G., Lindskog, E., Lacki, K., and Galliher, P. (2018). Biopharmaceutical Processing Development, Design, and Implementation of Manufacturing Process, Elsevier."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","article-title":"Intravenous immunoglobulin G: Trends in production methods, quality control and quality assurance","volume":"98","author":"Radosevich","year":"2010","journal-title":"Vox Sang."},{"key":"ref_46","unstructured":"(2023, August 15). Miller-Keystone Blood Center. Available online: https:\/\/www.giveapint.org\/ufaqs\/how-long-does-it-take-to-donate-plasma\/."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2013-09-527978","article-title":"A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy","volume":"123","author":"Kapur","year":"2014","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:38:06Z","timestamp":1760128686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":47,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcm12175492"],"URL":"https:\/\/doi.org\/10.3390\/jcm12175492","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}